Introduction

A developing baby relies on healthy kidneys long before birth. When those kidneys fail to form or function, the result can be life-threatening. Potter syndrome, also known as Potter sequence, describes the pattern of facial, limb and lung abnormalities that follow prolonged loss of amniotic fluid, a loss most often caused by severe kidney malformation¹. Autosomal recessive polycystic kidney disease (ARPKD) is one of the major causes of that fluid loss. In ARPKD, each kidney becomes enlarged and densely packed with microscopic fluid-filled sacs, or cysts, due to inherited changes in a single gene called PKHD1². Both disorders are rare but devastating. Families faced with a prenatal diagnosis must make rapid decisions about monitoring, delivery and long-term care.

This article explains how faulty genes disrupt kidney development, why those changes produce the characteristic features of Potter syndrome, and how doctors diagnose and manage ARPKD. Key points for readers are that Potter syndrome is not a separate disease but a predictable result of severe kidney failure in the womb, that ARPKD follows an autosomal recessive inheritance pattern with a one-in-four risk for each pregnancy, and that modern intensive care and transplantation now allow many affected children to survive into adulthood.

Answering the main question

Potter syndrome and ARPKD both stem from genetic errors that block normal kidney growth. In Potter syndrome, the kidneys may be absent, underdeveloped or cystic, leading to minimal urine production and minimal amniotic fluid. In ARPKD, the kidneys are present but filled with countless tiny cysts that impair urine flow and trigger the same fluid shortage. The shared pathway is early kidney failure, but the genetic trigger differs. Potter syndrome can arise from several renal malformations, whereas ARPKD is caused by biallelic PKHD1 variants that disrupt a protein called fibrocystin³. How serious the lung underdevelopment is and when medical help is received both influence the results.

Read on

Understanding how these genetic issues disrupt the normal development of the kidneys and lungs helps with both giving parents guidance before birth and planning the best care after birth. The next sections explain the science and practical steps to give affected babies the best possible outcome.

Embryology of renal development

Human kidneys form through a series of branching tubules that arise from the ureteric bud and the metanephric mesenchyme. This process starts around the fifth week of pregnancy and relies on carefully controlled signalling chemicals.⁴ When one of those signals is missing or blocked, the branching stalls and nephrons, the filtering units of the kidney, fail to appear. Complete failure on both sides produces bilateral renal agenesis, the classic trigger of Potter syndrome.¹ Partial failure results in small, abnormal kidneys that still affect urine production.

Amniotic fluid is mostly made up of urine from the baby after the first three months of pregnancy.. Without it, the baby's chest can't open up properly, so the lungs stay small and stiff. The face presses against the wall of the uterus, flattening the nose and cheeks, and the limited space causes clubbed feet and stiff joints. These secondary changes define the Potter sequence.

Genetics of ARPKD

ARPKD is inherited in an autosomal recessive manner, meaning both parents must pass on a faulty PKHD1 allele₂. The gene provides instructions for making fibrocystin, a protein found in the main hair-like structures (called primary cilia) of cells in the kidney's collecting tubes and the liver's bile ducts.⁵. Fibrocystin helps the tiny hair-like structures in the kidney called cilia detect the flow of fluid. Without it, the small tubes in the kidney can stretch out and form many tiny cysts. Since all the collecting ducts are affected, people with ARPKD have lots of these small cysts spread throughout the kidney, causing it to enlarge. This is different from another type of kidney cyst disease, where fewer, larger cysts develop on their own.

More than eight hundred pathogenic PKHD1 variants have been reported, ranging from mutations that stop the protein from working properly or changes that only alter one building block (amino acid) in the protein's structure.³ Truncating variants usually produce the most severe neonatal presentation. Genotype-phenotype studies show, however, that even siblings with identical mutations can follow different clinical courses, suggesting additional genetic or environmental modifiers.⁶

Prenatal diagnosis and counselling

Routine ultrasonography now detects most severe renal anomalies by the mid-second trimester. Hallmarks include enlarged echogenic kidneys, absent bladder filling and oligohydramnios, the technical term for low amniotic fluid⁷. Targeted imaging with high-frequency probes can identify cystic texture characteristic of ARPKD. When oligohydramnios appears before twenty-two weeks, the risk of lethal pulmonary hypoplasia is high.

Genetic confirmation is possible through chorionic villus sampling or amniocentesis, followed by sequencing of PKHD1 or broader gene panels.⁸ A confirmed diagnosis allows clear counselling: the recurrence risk in future pregnancies is twenty-five per cent, carrier testing is available for relatives, and neonatal care can be planned. Some centres offer serial trans-abdominal amnioinfusion to restore fluid volume and support lung growth, but evidence remains limited and the procedure carries risks.⁹

Postnatal presentation

Newborns with Potter sequence present with respiratory distress, flat nasal bridge, sunken chin and loose, wrinkled skin. If bilateral renal agenesis is the cause, infants typically die within hours because breathing machines cannot compensate for tiny lungs.¹⁰ Infants with ARPKD often survive their first few hours but need ventilatory support, as their lungs are still smaller than normal. Their bellies look swollen because of very large kidneys that can fill the whole side of their body.

Laboratory tests reveal impaired kidney function, low sodium, and sometimes low platelet counts if portal hypertension from liver involvement is present. Hypertension can develop within days because the cystic kidneys activate the renin-angiotensin system.⁵ Early ultrasonography confirms the size and texture of the kidneys and shows whether the liver already displays signs of congenital hepatic fibrosis.

Medical management in early life

Immediate priorities are respiratory support, fluid balance and blood pressure control. Continuous positive airway pressure or mechanical ventilation helps compensate for small lungs. Careful fluid restriction prevents further abdominal distension while maintaining perfusion. Intravenous antihypertensive drugs such as nicardipine or labetalol are used to control severe blood pressure rises.¹¹

Once stable, infants begin long-term nephrology follow-up. Growth monitoring is crucial because calorie needs are high, yet large kidneys compress the stomach, limiting feeds. High-calorie formulas or nasogastric feeding may be required. Sodium supplementation corrects salt-wasting due to impaired concentrating ability. Prophylactic antibiotics reduce the risk of urinary infections.

Progression to renal failure

Half of survivors with ARPKD reach kidney failure within the first decade.¹² The cysts expand slowly but relentlessly, and interstitial fibrosis replaces functioning tissue. Dialysis bridges the gap to transplantation. Peritoneal dialysis is often chosen in young children because vascular access for haemodialysis is difficult, but the expanded kidneys leave little abdominal space, causing discomfort and technical challenges. Combined kidney-liver transplantation is considered when portal hypertension or recurrent cholangitis from congenital hepatic fibrosis becomes life-threatening.¹³

Transplant outcomes are favourable. Five-year graft survival after kidney transplantation in ARPKD mirrors that in other paediatric causes, and combined procedures offer similar patient survival when performed in experienced centres¹³.

Long-term extra-renal complications

The liver is the second organ affected by PKHD1 mutations. Fibrosis around the small bile ducts begins in childhood and can lead to portal hypertension with splenomegaly, variceal bleeding and growth failure⁵. Regular ultrasound and endoscopy surveillance enable early intervention with beta-blockers or endoscopic band ligation. In adolescence, some patients develop cysts in the pancreas, and rare reports describe intracranial aneurysms. Lifelong multidisciplinary care involving nephrologists, hepatologists, dietitians and psychologists improves quality of life.

Future therapies

Research focuses on modifying disease progression. Experimental work in animal models shows that vasopressin V2-receptor antagonists, which slow cyst expansion in dominant polycystic kidney disease, also shrink collecting duct cysts in ARPKD⁶. Trials of tolvaptan in children are planned but require caution because of liver toxicity concerns. Gene therapy remains theoretical; PKHD1 is large, and effective delivery to both the kidney and the liver is challenging. Meanwhile, advances in prenatal genomics promise earlier, more precise diagnosis that will refine counselling and may guide future intrauterine therapies.¹⁴

Summary

Potter syndrome is a predictable series of birth defects that follow severe, early loss of amniotic fluid. ARPKD is one of its commonest genetic causes, arising when both copies of PKHD1 are defective. Fibrocystin deficiency triggers cyst formation in the kidney collecting ducts and the liver bile ducts. Prenatal ultrasound and genetic testing now identify most affected pregnancies, allowing families to discuss prognosis and management. Postnatal care centres on respiratory support, blood pressure control and nutritional help, followed by dialysis and transplantation when the kidneys fail. Combined kidney-liver transplantation offers long-term survival for children with advanced hepatic disease. Research into medical treatments that slow cyst growth may further improve outcomes in the coming decades.

FAQs

Is ARPKD always inherited from both parents?

Yes. Each parent must pass on one faulty PKHD1 gene.

Can Potter syndrome occur without ARPKD?

Yes. Any cause of severe fetal kidney failure can trigger it.

Does every baby with ARPKD need a transplant?

Many do, but timing varies. Some keep reasonable kidney function into adolescence.

Can doctors fix these kidney problems before birth?

Research on amnioinfusion is ongoing, but it is not standard care.

What is the chance of ARPKD in future pregnancies?

When both parents are carriers, the risk is twenty-five per cent for each pregnancy.